Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer

Bruno Gori, Serena Ricciardi, Ester Del Signore, Alberto Fulvi, Filippo De Marinis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.

Original languageEnglish
JournalExpert Opinion on Therapeutic Targets
Volume16
Issue numberSUPPL.2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Cells
Chemotherapy
Therapeutics
Pharmaceutical Preparations
Expert Testimony
Patient Rights
Disease-Free Survival
Disease Progression
gefitinib
Erlotinib Hydrochloride
Safety
Drug Therapy
Mutation
Population

Keywords

  • advanced NSCLC
  • EGFR mutation
  • erlotinib
  • first-line treatment
  • gefitinib

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. / Gori, Bruno; Ricciardi, Serena; Del Signore, Ester; Fulvi, Alberto; De Marinis, Filippo.

In: Expert Opinion on Therapeutic Targets, Vol. 16, No. SUPPL.2, 04.2012.

Research output: Contribution to journalArticle

Gori, Bruno ; Ricciardi, Serena ; Del Signore, Ester ; Fulvi, Alberto ; De Marinis, Filippo. / Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer. In: Expert Opinion on Therapeutic Targets. 2012 ; Vol. 16, No. SUPPL.2.
@article{dc1dd134b2ac4364a163c3ea5f876217,
title = "Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer",
abstract = "Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.",
keywords = "advanced NSCLC, EGFR mutation, erlotinib, first-line treatment, gefitinib",
author = "Bruno Gori and Serena Ricciardi and {Del Signore}, Ester and Alberto Fulvi and {De Marinis}, Filippo",
year = "2012",
month = "4",
doi = "10.1517/14728222.2011.652617",
language = "English",
volume = "16",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "SUPPL.2",

}

TY - JOUR

T1 - Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer

AU - Gori, Bruno

AU - Ricciardi, Serena

AU - Del Signore, Ester

AU - Fulvi, Alberto

AU - De Marinis, Filippo

PY - 2012/4

Y1 - 2012/4

N2 - Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.

AB - Introduction: In EGFR mutated advanced NSCLC, tyrosine kinase inhibitors are new valid options as first-line treatment. Gefitinib appears a valid alternative to chemotherapy as first-line therapy, in EGFR mutated elderly or unfit patients too, while erlotinib remains an option for subsequent lines of treatment. Areas covered: Areas covered in this review include two international trials, which evaluated erlotinib in chemo-naive EGFR mutated patients both in an Asian and caucasian population, showing a dramatic advantage in terms of progression-free survival and overall response rate as well as gefitinib. Results showed a good safety profile, with side effects of mild to moderate intensity, usually manageable with temporary interruption of treatment. Expert opinion: Investigating EGFR mutations is critical in order to obtain sufficient data. It has now become mandatory for molecular characterization, as part of baseline diagnostic procedures. This approach is also becoming increasingly important during progression of the disease as a sort of 'molecular follow up'. It plays a central role in the right choice of treatment, in an aim to give the best drug to the right patients, overcoming other well known prognostic factors.

KW - advanced NSCLC

KW - EGFR mutation

KW - erlotinib

KW - first-line treatment

KW - gefitinib

UR - http://www.scopus.com/inward/record.url?scp=84858958689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858958689&partnerID=8YFLogxK

U2 - 10.1517/14728222.2011.652617

DO - 10.1517/14728222.2011.652617

M3 - Article

C2 - 22443258

AN - SCOPUS:84858958689

VL - 16

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - SUPPL.2

ER -